• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by National Vision Holdings Inc.

    11/14/25 9:56:01 AM ET
    $EYE
    Ophthalmic Goods
    Health Care
    Get the next $EYE alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    National Vision Holdings, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    63845R107

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    63845R107


    1Names of Reporting Persons

    American Century Investment Management, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    3,229,133.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    4,391,844.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,391,844.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.6 %
    12Type of Reporting Person (See Instructions)

    IA


    SCHEDULE 13G

    CUSIP No.
    63845R107


    1Names of Reporting Persons

    American Century Companies, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    3,229,133.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    4,391,844.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,391,844.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.6 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    63845R107


    1Names of Reporting Persons

    Stowers Institute for Medical Research
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    3,229,133.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    4,391,844.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    4,391,844.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.6 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    National Vision Holdings, Inc.
    (b)Address of issuer's principal executive offices:

    2435 Commerce Avenue BLDG 2200, Duluth, GA, 30096
    Item 2. 
    (a)Name of person filing:

    American Century Investment Management, Inc. American Century Companies, Inc. Stowers Institute for Medical Research
    (b)Address or principal business office or, if none, residence:

    4500 Main Street 9th Floor Kansas City, Missouri 64111
    (c)Citizenship:

    Delaware
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    63845R107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See the response(s) to Item 9 on the attached cover page(s).
    (b)Percent of class:

    See the response(s) to Item 11 on the attached cover page(s).
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See the response(s) to Item 5 on the attached cover page(s).

     (ii) Shared power to vote or to direct the vote:

    See the response(s) to Item 6 on the attached cover page(s).

     (iii) Sole power to dispose or to direct the disposition of:

    See the response(s) to Item 7 on the attached cover page(s).

     (iv) Shared power to dispose or to direct the disposition of:

    See the response(s) to Item 8 on the attached cover page(s).

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    Various persons, including the investment companies and separate institutional investor accounts that American Century Investment Management, Inc. ("ACIM") serves as investment adviser, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities that are the subject of this schedule. Except as may be otherwise indicated if this is a joint filing, not more than 5% of the class of securities that is the subject of this schedule is owned by any one client advised by ACIM.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    This Item identifies each subsidiary of American Century Companies, Inc. ("ACC"), which is controlled by the Stowers Institute for Medical Research, that is a beneficial owner of securities that are subject of this schedule (the "Subject Securities"). American Century Investment Management, Inc. ("ACIM") is a wholly-owned subsidiary of ACC and an investment adviser registered under Section 203 of the Investment Advisers Act of 1940.
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    Not applicable
    Item 9.Notice of Dissolution of Group.
     
    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.


    Not applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    American Century Investment Management, Inc.
     
    Signature:American Century Investment Management, Inc.
    Name/Title:/s/ John Pak / Senior Vice President
    Date:11/14/2025
     
    American Century Companies, Inc.
     
    Signature:American Century Companies, Inc.
    Name/Title:/s/ John Pak / Senior Vice President
    Date:11/14/2025
     
    Stowers Institute for Medical Research
     
    Signature:Stowers Institute for Medical Research
    Name/Title:/s/ Joselyn Verschelden / Authorized Signer
    Date:11/14/2025
    Exhibit Information

    EXHIBIT Each of the undersigned hereby agrees and consents to the execution and joint filing on its behalf by American Century Investment Management, Inc. of this Schedule 13G respecting the beneficial ownership of the securities which are the subject of this schedule. Dated this 14th day of November, 2025. AMERICAN CENTURY INVESTMENT MANAGEMENT, INC. ("ACIM") AMERICAN CENTURY COMPANIES, INC. ("ACC") By: __/s/ John Pak_________________ John Pak Senior Vice President, ACIM and ACC STOWERS INSTITUTE FOR MEDICAL RESEARCH, solely in its capacity as control entity of ACC By: __/s/ Joselyn Verschelden__________ Joselyn Verschelden Authorized Signer

    Get the next $EYE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EYE

    DatePrice TargetRatingAnalyst
    7/30/2025$36.00Buy
    Roth Capital
    7/8/2025$30.00Equal Weight → Overweight
    Barclays
    5/9/2025$21.00Neutral → Buy
    Citigroup
    5/7/2025Underperform → Buy
    BofA Securities
    10/17/2023$25.00 → $16.00Buy → Neutral
    Goldman
    7/27/2023$28.00 → $22.00Buy → Neutral
    Citigroup
    7/27/2023$30.00 → $21.00Overweight → Equal Weight
    Wells Fargo
    5/2/2023Overweight → Equal Weight
    Barclays
    More analyst ratings

    $EYE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on National Vision with a new price target

    Roth Capital initiated coverage of National Vision with a rating of Buy and set a new price target of $36.00

    7/30/25 7:33:08 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision upgraded by Barclays with a new price target

    Barclays upgraded National Vision from Equal Weight to Overweight and set a new price target of $30.00

    7/8/25 8:23:14 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision upgraded by Citigroup with a new price target

    Citigroup upgraded National Vision from Neutral to Buy and set a new price target of $21.00

    5/9/25 8:39:42 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    $EYE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Manager Patel Priti V covered exercise/tax liability with 538 shares and converted options into 1,502 shares, increasing direct ownership by 7% to 13,869 units (SEC Form 4)

    4 - National Vision Holdings, Inc. (0001710155) (Issuer)

    10/6/25 4:44:22 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    Executive Chairman Fahs L Reade sold $301,278 worth of shares (12,600 units at $23.91), decreasing direct ownership by 2% to 532,195 units (SEC Form 4)

    4 - National Vision Holdings, Inc. (0001710155) (Issuer)

    9/17/25 4:11:52 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    SEC Form 4 filed by Chief Technology Officer Cutler David G

    4 - National Vision Holdings, Inc. (0001710155) (Issuer)

    9/9/25 4:23:22 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    $EYE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    National Vision Holdings, Inc. to Host Investor Day November 17, 2025

    Following The Event The Company Will Ring the Nasdaq Closing Bell National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company"), will host an Investor Day on Monday, November 17, 2025, in New York City, as previously announced. The event, to be held at the NASDAQ MarketSite in Times Square, will highlight the Company's transformation strategies and financial outlook, featuring a series of presentations as well as a question-and-answer session with members of the Company's senior leadership team, including Alex Wilkes, Chief Executive Officer, and Chris Laden, Chief Financial Officer. The event will begin at 10:00 a.m. ET and is expected to conclude by 1:30 p.m. ET. Du

    11/10/25 8:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision Holdings, Inc. Reports Third Quarter 2025 Financial Results

    Transformation Initiatives Continue to Drive Strong Performance Raises Fiscal 2025 Outlook Third quarter 2025 highlights compared to third quarter 2024: Net revenue from continuing operations increased 7.9% to $487.3 million Comparable store sales growth of 6.8% and Adjusted Comparable Store Sales Growth of 7.7% represented the 11th consecutive quarter of positive growth Income from continuing operations of $3.4 million, Diluted EPS from continuing operations of $0.04, with Income (loss) from continuing operations margin improving to 0.7% from (1.9)% Adjusted Operating Income from continuing operations of $19.8 million, up 38.6%, with Adjusted Operating Margin improving to 4.1% fro

    11/5/25 6:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision Holdings, Inc. Announces Third Quarter 2025 Earnings Release and Conference Call

    National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") will report its third quarter 2025 financial results before the market opens on Wednesday, November 5, 2025, and will host a conference call at 8:30 a.m. Eastern Time. To pre-register for the conference call and obtain a dial-in number and passcode, please refer to the "Investors" section of the Company's website at https://ir.nationalvision.com. A live audio webcast of the conference call, together with related materials, will be available online in the "Investors" section of the Company's website. A replay of the audio webcast will be available shortly after the broadcast. About National Vision Holdings,

    10/22/25 8:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    $EYE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Peeler D Randolph bought $264,200 worth of shares (25,000 units at $10.57) (SEC Form 4)

    4 - National Vision Holdings, Inc. (0001710155) (Issuer)

    8/14/24 4:27:52 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    Director Hepner Virginia A bought $10,365 worth of shares (1,000 units at $10.37), increasing direct ownership by 3% to 36,635 units (SEC Form 4)

    4 - National Vision Holdings, Inc. (0001710155) (Issuer)

    8/14/24 4:26:51 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    Fahs L Reade bought $299,200 worth of shares (20,000 units at $14.96), increasing direct ownership by 3% to 633,097 units (SEC Form 4)

    4 - National Vision Holdings, Inc. (0001710155) (Issuer)

    5/14/24 8:01:46 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    $EYE
    SEC Filings

    View All

    SEC Form SCHEDULE 13G filed by National Vision Holdings Inc.

    SCHEDULE 13G - National Vision Holdings, Inc. (0001710155) (Subject)

    11/14/25 9:56:01 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    SEC Form SCHEDULE 13G filed by National Vision Holdings Inc.

    SCHEDULE 13G - National Vision Holdings, Inc. (0001710155) (Subject)

    11/12/25 4:32:23 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    SEC Form SCHEDULE 13G filed by National Vision Holdings Inc.

    SCHEDULE 13G - National Vision Holdings, Inc. (0001710155) (Subject)

    11/12/25 9:33:33 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    $EYE
    Leadership Updates

    Live Leadership Updates

    View All

    National Vision, Inc. Unveils Bold New Brand Identity as Part of Strategic Transformation

    Brand refresh underscores National Vision's continued business evolution and unwavering commitment to accessible, high-quality eye care and eyewear DULUTH, Ga., Aug. 5, 2025 /PRNewswire/ -- National Vision Holdings, Inc. (NASDAQ:EYE), one of the largest optical retail companies in the United States, unveiled its new corporate brand identity, a major milestone in National Vision's transformation journey. The refreshed branding strengthens National Vision's position as a modern, agile and purpose-driven organization committed to helping people see their best to live their best. Experience the full interactive Multichannel News Release here: https://www.multivu.com/national-vision-holdings/934

    8/5/25 8:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision Appoints Alex Wilkes as CEO

    Reade Fahs to Assume Executive Chairman Position Transition Effective August 1, 2025 National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced that its Board of Directors has appointed Alex Wilkes as the Company's next Chief Executive Officer, effective August 1, 2025, and he will join the Company's Board at that time. Mr. Wilkes succeeds Reade Fahs who will assume the role of Executive Chairman of the Board. Mr. Fahs will continue to work closely with Mr. Wilkes, ensuring a smooth transition. "National Vision has been on a journey of significant transformation for the past few years, and today I am pleased to announce the next chapter in that tran

    4/29/25 6:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision Appoints Jim McGrann and Michael Nicholson to Board of Directors

    Enters into Cooperation Agreement with Engine Capital National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") today announced the appointment of two new independent directors, Jim McGrann and Michael Nicholson to its Board of Directors (the "Board"), effective March 17, 2025. Mr. McGrann will serve on the Board's Compensation Committee and Mr. Nicholson will serve on the Board's Audit Committee and Nominating and Corporate Governance Committee. With the addition of Messrs. McGrann and Nicholson, the Board will expand from 9 to 11 members. The Board has also formed an Advisory Committee that will help oversee National Vision's ongoing transformation initiatives with

    3/17/25 4:05:00 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    $EYE
    Financials

    Live finance-specific insights

    View All

    National Vision Holdings, Inc. Reports Third Quarter 2025 Financial Results

    Transformation Initiatives Continue to Drive Strong Performance Raises Fiscal 2025 Outlook Third quarter 2025 highlights compared to third quarter 2024: Net revenue from continuing operations increased 7.9% to $487.3 million Comparable store sales growth of 6.8% and Adjusted Comparable Store Sales Growth of 7.7% represented the 11th consecutive quarter of positive growth Income from continuing operations of $3.4 million, Diluted EPS from continuing operations of $0.04, with Income (loss) from continuing operations margin improving to 0.7% from (1.9)% Adjusted Operating Income from continuing operations of $19.8 million, up 38.6%, with Adjusted Operating Margin improving to 4.1% fro

    11/5/25 6:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision Holdings, Inc. Announces Third Quarter 2025 Earnings Release and Conference Call

    National Vision Holdings, Inc. (NASDAQ:EYE) ("National Vision" or the "Company") will report its third quarter 2025 financial results before the market opens on Wednesday, November 5, 2025, and will host a conference call at 8:30 a.m. Eastern Time. To pre-register for the conference call and obtain a dial-in number and passcode, please refer to the "Investors" section of the Company's website at https://ir.nationalvision.com. A live audio webcast of the conference call, together with related materials, will be available online in the "Investors" section of the Company's website. A replay of the audio webcast will be available shortly after the broadcast. About National Vision Holdings,

    10/22/25 8:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    National Vision Holdings, Inc. Reports Second Quarter 2025 Financial Results

    Accelerated Initiatives Drive Comparable Store Sales Growth and Improved Profitability Raises Fiscal 2025 Outlook Second quarter 2025 highlights compared to second quarter 2024: Net revenue from continuing operations increased 7.7% to $486.4 million Comparable store sales growth of 6.5% and Adjusted Comparable Store Sales Growth of 5.9% represented the 10th consecutive quarter of positive growth Income from continuing operations of $8.7 million, Diluted EPS from continuing operations of $0.11 Adjusted Operating Income from continuing operations of $23.8 million, up 69.1%, with Adjusted Operating Margin improving to 4.9% from 3.1% Adjusted Diluted EPS from continuing operati

    8/6/25 6:00:00 AM ET
    $EYE
    Ophthalmic Goods
    Health Care

    $EYE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by National Vision Holdings Inc.

    SC 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

    11/14/24 12:33:08 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SC 13G/A filed by National Vision Holdings Inc.

    SC 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

    11/12/24 4:45:48 PM ET
    $EYE
    Ophthalmic Goods
    Health Care

    Amendment: SEC Form SC 13G/A filed by National Vision Holdings Inc.

    SC 13G/A - National Vision Holdings, Inc. (0001710155) (Subject)

    11/4/24 1:18:26 PM ET
    $EYE
    Ophthalmic Goods
    Health Care